PDX model details
| PDX ID |
407M |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
9 |
| Average PDX Generation Time (days +/- SEM) |
73 ± 6 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
407M |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 407M |
GEMIN5 |
0.781684 |
3.43827 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
CHD7 |
1.68431 |
6.42773 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
MYC |
1.59361 |
6.03607 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
AKT1 |
0.908648 |
3.75457 |
gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
JAK1 |
-0.771586 |
1.17155 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
SETD2 |
-0.843944 |
1.11424 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
CHD1 |
-0.833774 |
1.12212 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
APC |
-0.833774 |
1.12212 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
RB1 |
-1.92501 |
0.526677 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
TP53 |
-0.82209 |
1.13124 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
NCOR1 |
-0.82209 |
1.13124 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
SMAD2 |
-0.779661 |
1.16501 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 407M |
MBD1 |
-0.779661 |
1.16501 |
loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
407M |
| Sample Site |
Liver |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, abiraterone, enzalutamide |
| |
|
Patient Information
| Patient Number |
407 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Depth
|
ALT_FREQ
|
Consequence
|
Exon
|
GnomAD_AF
|
CADD_PHRED
|
Clinvar_clnsig
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 407M |
TP53 |
249 |
1.0 |
stop_gained |
'4/11 |
. |
35 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
SMAD2 |
199 |
0.98 |
stop_gained |
'11/11 |
. |
42 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
APC |
206 |
0.93 |
frameshift_variant |
'16/16 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
AKT1 |
552 |
0.64 |
missense_variant,splice_region_variant |
'2/13 |
4.08E-06 |
25.9 |
Pathogenic/Likely_pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
CACNA1H |
347 |
0.54 |
missense_variant |
'10/35 |
0.0002622 |
4.878 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
NF1 |
286 |
0.49 |
missense_variant |
'51/58 |
0.0007889 |
25.4 |
Conflicting_interpretations_of_pathogenicity
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
MAST4 |
522 |
0.48 |
missense_variant |
'2/29 |
0.0008207 |
33 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 407M |
NOTCH3 |
406 |
0.32 |
missense_variant |
'6/33 |
0.0003093 |
24.7 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table